Cargando…
Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine
The Coronavirus Disease 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Related Coronavirus 2 (SARS-CoV-2) is a global health emergency. As only very limited therapeutic options are clinically available, there is an urgent need for the rapid development of safe, effective, a...
Autores principales: | Schloer, Sebastian, Brunotte, Linda, Goretzko, Jonas, Mecate-Zambrano, Angeles, Korthals, Nadia, Gerke, Volker, Ludwig, Stephan, Rescher, Ursula |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594754/ https://www.ncbi.nlm.nih.gov/pubmed/32975484 http://dx.doi.org/10.1080/22221751.2020.1829082 |
Ejemplares similares
-
Pharmacologically induced endolysosomal cholesterol imbalance through clinically licensed drugs itraconazole and fluoxetine impairs Ebola virus infection in vitro
por: Kummer, Susann, et al.
Publicado: (2022) -
Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitro
por: Schloer, Sebastian, et al.
Publicado: (2021) -
Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro
por: Brunotte, Linda, et al.
Publicado: (2021) -
The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo
por: Schloer, Sebastian, et al.
Publicado: (2019) -
Repurposing Antifungals for Host-Directed Antiviral Therapy?
por: Schloer, Sebastian, et al.
Publicado: (2022)